Recombinant Human Monoclonal Antibodies Against Emerging Infectious Diseases: Harnessing the Human Immune System to Fast-Track Assay Development 

Description

Emerging infectious diseases pose a significant global threat as they have the potential to cause widespread morbidity and mortality, disrupt economies, and overwhelm healthcare systems. The unpredictable nature of these diseases, exemplified by recent outbreaks of viruses like Ebola, Zika, and COVID-19, underscores the urgent need for effective surveillance, rapid diagnostic tools, and innovative treatments to mitigate their impact and protect public health.

Modern technologies allow for the isolation and cloning of neutralizing antibodies that are present in patients previously vaccinated for or infected by these pathogens. These antibodies are crucial in the development of rapid diagnostic tests (RDTs) that can detect pathogens quickly and accurately as well as in basic research on these pathogens.

Fill out the form to download the monograph and learn more about the various monoclonal antibodies against a range of emerging infectious diseases and the antibody screening and assay development services at Leinco.